Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.39 |
| ▸ | GLB1 | P16278 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22397156 | 0.73 | KMT2A (0.42) | KDM4ELMNAKMT2ACYP1A2MAPT | |
| SCHEMBL24191850 | 0.71 | KDM4E (0.38) | KDM4ELMNAKMT2ACYP1A2MAPT | |
| SCHEMBL1284263 | 0.70 | ALDH1A1 (0.41) | KDM4ELMNAKMT2ACYP1A2MAPT | |
| SCHEMBL16863288 | 0.70 | KMT2A (0.40) | KDM4ELMNAKMT2ACYP1A2MAPT | |
| SCHEMBL12659213 | 0.69 | CHRM3 (0.43) | KDM4ELMNAKMT2ACYP1A2MAPT | |
| SCHEMBL9797391 | 0.68 | KDM4E (0.48) | KDM4ELMNAKMT2ACYP1A2MAPT | |
| SCHEMBL30577792 | 0.68 | KDM4E (0.41) | KDM4ELMNAKMT2AMAPTMEN1 | |
| SCHEMBL23757667 | 0.68 | ATM (0.42) | KDM4ELMNAKMT2ACYP1A2MAPT | |
| SCHEMBL30079717 | 0.67 | TSHR (0.43) | KDM4ELMNAKMT2ACYP1A2MAPT | |
| SCHEMBL9748650 | 0.67 | KMT2A (0.40) | KDM4ELMNAKMT2ACYP1A2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227347-B2 | Purinyl-N-hydroxyl pyrimidine formamide derivative, preparation methods and uses thereof | GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD. (CN) | 2019-03-12 | — | — | US | disclosed |
| US-20180134709-A1 | PURINYL-N-HYDROXYL PYRIMIDINE FORMAMIDE DERIVATIVE, PREPARATION METHODS AND USES THEREOF | CHENGDU ZENITAR BIOMEDICAL TECHNOLOGY CO., LTD. (CN) | 2018-05-17 | — | — | US | disclosed |
| CN-103582483-B | Phosphatidylinositol 3-kinase inhibitors with zinc binding sites | CURIS, INC. (US) | 2016-02-17 | — | — | CN | disclosed |
| CN-103582483-A | Phosphatidylinositol 3-kinase inhibitors with zinc binding sites | CURIS INC | 2014-02-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134709-A1 | PURINYL-N-HYDROXYL PYRIMIDINE FORMAMIDE DERIVATIVE, PREPARATION METHODS AND USES THEREOF | HDAC5, HDAC2, HDAC8 | FUCA1 2507/4885GLB1 4272/4885KDM4E 428/4885 |
| US-10227347-B2 | Purinyl-N-hydroxyl pyrimidine formamide derivative, preparation methods and uses thereof | HDAC5, HDAC2, HDAC8 | FUCA1 2507/4885GLB1 4272/4885KDM4E 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.